Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity Dapirolizumab pegol (DZP) met its...
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd...
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference -New testing method highlights link...
Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases The collaboration aims to...
Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has appointed Daniel Quirk, M.D., M.P.H., M.B.A. as...
Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025 Robin Kramer, Chief Accounting Officer, to Succeed HimCAMBRIDGE, Mass., Oct. 28, 2024 (GLOBE...
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024 The detailed study results confirmed interim...
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB...
Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024 Late breaker oral presentation to feature final results of the Phase 2 IGNAZ study...
Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients Designation is based on data from the...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -12.05 | -7.5786163522 | 159 | 160.3 | 146.95 | 43 | 154.53023256 | DE |
| 4 | -23.25 | -13.66039953 | 170.2 | 173.4 | 146.95 | 38 | 163.58728814 | DE |
| 12 | -37.5 | -20.3307129303 | 184.45 | 185.95 | 146.95 | 46 | 169.59613929 | DE |
| 26 | -66.25 | -31.074108818 | 213.2 | 220.7 | 146.95 | 38 | 183.21897906 | DE |
| 52 | -68.65 | -31.8413729128 | 215.6 | 244.6 | 146.95 | 34 | 193.42657213 | DE |
| 156 | -68.65 | -31.8413729128 | 215.6 | 244.6 | 146.95 | 34 | 193.42657213 | DE |
| 260 | -68.65 | -31.8413729128 | 215.6 | 244.6 | 146.95 | 34 | 193.42657213 | DE |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
